E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) |
Carcinoma pulmonar no microcitico localmente avanzado o metastasico (estadio IIIB-IV), |
|
E.1.1.1 | Medical condition in easily understood language |
Non-Small Cell Lung Cancer |
Carcinoma pulmonar no microcitico |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066490 |
E.1.2 | Term | Progression of non-small cell lung cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029514 |
E.1.2 | Term | Non-small cell lung cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of MEDI4736 treatment in terms of objective response rate (ORR) |
Evaluar la eficacia del tratamiento con MEDI4736 en terminos de Tasa de Respuesta Objetiva (TRO). |
|
E.2.2 | Secondary objectives of the trial |
To further assess the efficacy of MEDI4736 in terms of: Duration of response (DoR), Progression free survival (PFS), Disease control rate (DCR), Overall survival (OS), and Deep sustained response (DSR) To assess the safety, tolerability, PK and immunogenicity profile of MEDI4736 |
Evaluar la eficacia de MEDI4736 en terminos de: Duracion de la respuesta (DR), Supervivencia sin Progresion (SSP), Tasa de Control de la Enfermedad (TCE), Supervivencia General (SG) y Respuesta Profunda Sostenida (RPS) Evaluar la seguridad, tolerabilidad, FC e inmunogenicidad de MEDI4736 |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenetics Research |
Investigacion Farmacocinética |
|
E.3 | Principal inclusion criteria |
1. Provision of signed, written and dated informed consent prior to any study specific procedures 2. Male or female aged 18 years or older 3. Patients must have EITHER ? Histologically- or cytologically-documented NSCLC), OR ? Recurrent or progressive disease following multimodal therapy for locally advanced disease) 4. Patients must have received at least 2 prior systemic treatment regimens for treatment of NSCLC 5. Patients must have experienced disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional systemic therapy 6. Patients must provide a tumour sample 7. Patients must have measurable disease 8. Life expectancy ?12 weeks 9. World Health Organisation (WHO) Performance Status of 0 or 1 10. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients 11. Adequate organ and marrow function |
1.Proporcionar un consentimiento informado firmado y fechado antes de realizar cualquier procedimiento del estudio 2.Ser hombre o mujer de 18 años de edad o mas 3.Los pacientes deben tener O BIEN ?CPNM histologicamente o citologicamente documentado de la enfermedad O ?Una enfermedad recurrente o progresiva despues de un tratamiento multimodal (radioterapia, reseccion quirurgica o quimiorradioterapia definitiva para la enfermedad localmente avanzada) 4.Los pacientes deben haber recibido al menos 2 pautas de tratamiento sistemico previas para el tratamiento del CPNM 5.Los pacientes deben haber experimentado progresion de la enfermedad o recurrencia despues de un regimen de quimioterapia a base de platino y, al menos, 1 tratamiento sistemico adicional 6. Los pacientes deben proporcionar una muestra tumoral. 7.Los pacientes deben tener una enfermedad medible 8.Esperanza de vida ? 12 semanas 9.Estado general de 0 o 1 de la Organización Mundial de la Salud (OMS) 10. Pruebas de condición posmenopausica o prueba de embarazo en orina o suero negativa en las mujeres premenopausicas. 11. Funcion adecuada de los organos y la medula |
|
E.4 | Principal exclusion criteria |
1. Participation in another clinical study with an investigational product (IMP) during the last 4 weeks 2. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study 3. Mixed small cell and NSCLC histology 4. Receipt of any immunotherapy, or IMP within 4 weeks prior to the first dose of study drug 5. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody 6. Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy 7. Any prior Grade ?3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1 8. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment 9. Receipt of radiation therapy within 4 weeks prior to starting MEDI4736, or limited field of radiation for palliation within 2 weeks of the first dose of MEDI4736 10. Recent major surgery within 4 weeks 11. Active or prior documented autoimmune disease within the past 2 years, except for: Vitiligo, Grave's disease, or psoriasis not requiring systemic treatment 12. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) 13. History of primary immunodeficiency 14. History of organ transplant that requires therapeutic Immunosuppression 15. History of hypersensitivity to MEDI4736 or any excipient 16. Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 1 month prior to entry into the study 17. Uncontrolled intercurrent illness 18. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving MEDI4736 19. History of another primary malignancy within 5 years prior to starting MEDI4736, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study 20. Female patients who are pregnant or breast-feeding. Male or female patients of reproductive potential who are not using an effective method of birth control 21. Any condition that, in the opinion of the investigator, would interfere with evaluation of MEDI4736 or interpretation of patient safety or study results |
1.Participacion en otro estudio clinico con un producto en investigacion durante las ultimas 4 semanas 2Inscripcion simultanea en otro estudio clinico, a menos que sea un estudio clinico observacional (no intervencionista) o el periodo de seguimiento de un estudio de intervencion 3.Histologia del CPNM con celulas pequeñas mixtas 4.Haber recibido una inmunoterapia o un farmaco en investigacion en las 4 semanas previas a la primera dosis del farmaco del estudio; y, en el caso de anticuerpos monoclonales, 6 semanas antes de la primera dosis del farmaco del estudio 5.Exposicion previa a cualquier anticuerpo PD-1 o anti-PD-L1 6.Cualquier toxicidad no resuelta de > grado 2 de los CTCAA derivada del tratamiento anterior contra el cancer. 7.Cualquier acontecimiento adverso relacionado con la inmunidad (AAri) de grado ? 3 durante la recepcion de un agente de inmunoterapia previo, o cualquier AAri no resuelto > grado 1 8.Cualquier quimioterapia, inmunoterapia, tratamiento biologico u hormonal concurrentes para el tratamiento del cancer 9.Haber recibido una radioterapia en las 4 semanas antes de comenzar el producto en investigacion o un campo limitado de radiacion paliativo en las 2 semanas antes de la primera dosis del producto en investigacion 10.Cirugia mayor reciente en las 4 semanas antes de la entrada en el estudio. 11.Enfermedad autoinmune, activa o previamente documentada, en los ultimos 2 años. NOTA: no estan excluidos los pacientes con vitiligo, la enfermedad de Grave o psoriasis que no requieren un tratamiento sistemico (en los ultimos 2 años) 12.Enfermedad intestinal inflamatoria activa o previamente documentada (p. ej. la enfermedad de Crohn o la colitis ulcerosa) 13.Antecedentes de inmunodeficiencia primaria 14.Antecedentes de trasplante de organos que requieran inmunosupresion terapeutica 15.Antecedentes de hipersensibilidad a MEDI4736 o cualquier excipiente 16.Metastasis cerebrales o compresion de la medula espinal, a menos que sea asintomatica, este tratada y estable, sin esteroides y anticonvulsivos durante, al menos, 1 mes antes de la entrada en el estudio 17.Enfermedad intercurrente no controlada 18.Haber recibido una vacuna viva atenuada en los 30 dias antes de la entrada en el estudio o en los 30 dias antes de recibir MEDI4736 19.Antecedentes de otro tumor maligno primario en los 5 años antes de iniciar el producto en investigacion, con excepcion del carcinoma basocelular o el carcinoma de celulas escamosas de la piel, o del cancer de cuello uterino in situ, que se hayan tratado adecuadamente, y de la enfermedad en estudio 20.Las pacientes que esten embarazadas o dando el pecho, o los hombres y las mujeres con potencial reproductivo que no utilicen un metodo anticonceptivo efectivo 21.Cualquier condición que, en opinion del investigador, podria interferir en la evaluacion del producto en investigacion o la interpretacion de la seguridad del paciente o de los resultados del estudio |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective response rate (ORR) (per RECIST 1.1) |
Tasa de respuesta objetiva (TRO) (RECIST 1.1) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The data cut-off for analysis of ORR will take place approximately 8 months after recruitment ends. |
Los datos de corte para el analisis de la TRO se llevaran a cabo aproximadamente 8 meses despues del fin del reclutamiento |
|
E.5.2 | Secondary end point(s) |
- Duration of response - Progression free survival - Disease control rate - Overall survival - Deep sustained response - AEs |
- Duracion de la respuesta - Supervivencia sin progresion - Tasa de control de la enfermedad - Supervivencia General - Respuesta Profunda Sostenida - AA |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The data cut-off for analysis of the secondary efficacy endpoints will take place approximately 8 months after recruitment ends. The final analysis of OS (secondary endpoint) will take place 12 months after recruitment ends. |
Los datos de corte para el analisis de los criterios de valoracion de la eficacia tendran lugar aproximadamente 8 meses despues del fin de reclutamiento. El analisis final de la SG (criterio de valoracion secundario) tendra lugar 12 meses despues del fin de reclutamiento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 57 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
European Union |
Japan |
Korea, Republic of |
Malaysia |
Philippines |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as ?the last visit of the last patient undergoing the study?. |
El final del estudio se define como la ultima visita del ultimo sujeto del estudio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |